Coherus BioSciences Stock News

Blueshift Asset Management LLC purchased a new stake in Coherus Biosciences Inc (NASDAQ:CHRS) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exch

Coherus Biosciences (NASDAQ:CHRS) was upgraded by investment analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a report released on Friday, BidAskClub reports. Several o

Coherus BioSciences (CHRS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Coherus BioSciences (CHRS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Mizuho Securities analyst Salim Syed maintained a Hold rating on Biogen (BIIB) today and set a price target of $316.00. The company's shares closed last

Mizuho Securities analyst Salim Syed maintained a Hold rating on Biogen (BIIB – Research Report) today and set a price

Envestnet Asset Management Inc. boosted its position in Coherus Biosciences Inc (NASDAQ:CHRS) by 5.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Se

Mizuho Securities analyst Salim Syed maintained a Buy rating on Coherus Biosciences (CHRS) yesterday and set a price target of $35.00. The company's

Mizuho Securities analyst Salim Syed maintained a Buy rating on Coherus Biosciences (CHRS – Research Report) yesterday and set a

(Bloomberg) -- For investors looking for deals in biotech, Wall Street firms like Baird advise “cash is king.”Losses in the U.S. stock market have decimated many portfolios. And while biotechnolog

Stating the obvious, Baird analysts have created three lists of healthcare companies that may be worth a look considering their attractive valuations or relatively strong capitalizations amid the COVI

Coherus Biosciences Inc (NASDAQ:CHRS) was up 14.3% during mid-day trading on Tuesday . The stock traded as high as $16.74 and last traded at $16.26, approximately 1,467,417 shares changed hands during

Market Still Sliding While Waiting For Congress

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Aerie Pharma (AERI) and Gilead Sciences (GILD) with bullish